Replies to post #522609 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

There is nothing else that is as efficacious as the DCVax-L therapy against the non-IDH-mutant GBM. The approvals will begin with the MHRA. The helmet will be pushed down to a lower tier in the list of patient choices.

[Dr Bala]

Besides being the most efficacious against the non-IDH-mutant GBM, the DCVax-L therapy is cheaper by far compared to the helmet treatment. Patients won't choose the expensive treatment with the helmet.

[Doc logic]

HyGro,

While we wait on manufacturing validation after the 17 missing SOC/placebo patients down payment on approval 7 years ago, not much left except high fives once MIA gets approved. Rolling submissions are kind of expected to have been done over such a lengthy delay to get manufacturing up to SOC production level and expected pricing. MA is designed to be able to catch up to MIA approval so surprise, surprise, the exceptions rule to adequate and well controlled trials gets the last laugh at your doubts and those of your post hoc brothers. Best wishes.